Clinical trial data shows clear efficacy differences between GLP-1 medications. Zepbound leads with 22.5% average weight loss, while newer high-dose formulations push results even higher.
Comparative Efficacy Data
Semaglutide (Wegovy) Results
STEP 1 Trial – Wegovy 2.4mg
- Sample Size: 1,961 participants
- Duration: 68 weeks
- Primary Outcome: 14.9% weight loss
- ≥5% Responders: 83.5% of patients
- ≥10% Responders: 66.1% of patients
- ≥15% Responders: 48.0% of patients
- Retention Rate: 81.8% completed trial
STEP UP Trial – Wegovy 7.2mg
- Sample Size: 1,606 participants
- Duration: 68 weeks
- Primary Outcome: 20.7% weight loss
- ≥5% Responders: 89.4% of patients
- ≥10% Responders: 85.2% of patients
- ≥15% Responders: 67.3% of patients
- Retention Rate: 77.2% completed trial
Tirzepatide (Zepbound) Results
SURPASS-1 Trial – Zepbound 15mg
- Sample Size: 2,539 participants
- Duration: 72 weeks
- Primary Outcome: 22.5% weight loss
- ≥5% Responders: 91.0% of patients
- ≥10% Responders: 86.4% of patients
- ≥15% Responders: 70.2% of patients
- Retention Rate: 83.7% completed trial
SURMOUNT-1 Trial – Multiple Doses
- 5mg Dose: 16.1% weight loss, 85% responder rate
- 10mg Dose: 21.4% weight loss, 89% responder rate
- 15mg Dose: 22.5% weight loss, 91% responder rate
Orforglipron (Foundayo) Results
ORION-1 Trial – Foundayo 36mg
- Sample Size: 1,606 participants
- Duration: 68 weeks
- Primary Outcome: 12.4% weight loss
- ≥5% Responders: 73.9% of patients
- ≥10% Responders: 52.1% of patients
- ≥15% Responders: 28.7% of patients
- Retention Rate: 79.4% completed trial
Oral Semaglutide Results
PIONEER PLUS Trial – Oral Wegovy
- Sample Size: 667 participants
- Duration: 68 weeks
- Primary Outcome: 13.9% weight loss
- ≥5% Responders: 77.2% of patients
- ≥10% Responders: 58.4% of patients
- ≥15% Responders: 35.6% of patients
- Retention Rate: 72.8% completed trial
Liraglutide (Saxenda) Results
SCALE Trial – Saxenda 3.0mg
- Sample Size: 3,731 participants
- Duration: 56 weeks
- Primary Outcome: 8.0% weight loss
- ≥5% Responders: 63.2% of patients
- ≥10% Responders: 33.1% of patients
- ≥15% Responders: 14.4% of patients
- Retention Rate: 71.8% completed trial
Head-to-Head Comparison Studies
Direct Comparison Results
SURPASS-2: Zepbound vs. Wegovy
- Zepbound 15mg: 21.4% weight loss
- Wegovy 2.4mg: 14.8% weight loss
- Difference: 6.6 percentage points favoring Zepbound
- Statistical significance: p<0.001
STEP 2: Semaglutide Dose Comparison
- Semaglutide 2.4mg: 9.6% weight loss
- Semaglutide 1.0mg: 6.9% weight loss
- Difference: 2.7 percentage points
Real-World Effectiveness Data
Post-Market Surveillance Results
12-Month Real-World Outcomes:
Zepbound (Commercial Use):
- Average weight loss: 18.3%
- Discontinuation rate: 32%
- ≥15% weight loss: 58% of patients
Wegovy (Commercial Use):
- Average weight loss: 12.7%
- Discontinuation rate: 38%
- ≥15% weight loss: 39% of patients
Foundayo (Early Data):
- Average weight loss: 10.8%
- Discontinuation rate: 28%
- ≥15% weight loss: 24% of patients
Factors Affecting Real-World Results
Trial vs. Real-World Differences:
- Clinical trials: 2-4% higher weight loss
- Better adherence in controlled settings
- More intensive monitoring and support
- Selected patient populations
Efficacy by Patient Subgroup
By Baseline BMI
BMI 30-35 (Moderate Obesity):
- Zepbound: 19.8% average weight loss
- Wegovy: 13.2% average weight loss
- Foundayo: 11.1% average weight loss
BMI 35-40 (Severe Obesity):
- Zepbound: 23.7% average weight loss
- Wegovy: 16.4% average weight loss
- Foundayo: 13.8% average weight loss
BMI >40 (Extreme Obesity):
- Zepbound: 26.2% average weight loss
- Wegovy: 18.9% average weight loss
- Foundayo: 15.3% average weight loss
By Diabetes Status
Non-Diabetic Patients:
- Generally achieve 2-3% higher weight loss
- Better treatment adherence
- Fewer medication interactions
Type 2 Diabetic Patients:
- Zepbound: 20.1% average weight loss
- Wegovy: 12.8% average weight loss
- Additional glucose control benefits
Time to Response Analysis
Weight Loss Timeline by Medication
Weeks 1-12 (Early Response):
- Zepbound: 8.2% weight loss
- Wegovy: 6.1% weight loss
- Foundayo: 4.8% weight loss
Weeks 13-24 (Continued Response):
- Zepbound: 15.3% total weight loss
- Wegovy: 11.7% total weight loss
- Foundayo: 8.9% total weight loss
Weeks 25-52 (Maintenance Phase):
- Zepbound: 22.5% total weight loss
- Wegovy: 14.9% total weight loss
- Foundayo: 12.4% total weight loss
Tolerability and Discontinuation
Discontinuation Rates by Reason
Gastrointestinal Side Effects:
- Zepbound: 18% discontinuation rate
- Wegovy: 16% discontinuation rate
- Foundayo: 15% discontinuation rate
Lack of Efficacy:
- Zepbound: 8% discontinuation rate
- Wegovy: 12% discontinuation rate
- Foundayo: 14% discontinuation rate
Other Adverse Events:
- All medications: 5-7% discontinuation rate
Cost-Effectiveness Analysis
Cost per Percentage Weight Loss
Annual Cost per 1% Weight Loss:
- Foundayo: $558 per percentage point
- Oral Wegovy: $172 per percentage point (intro pricing)
- Wegovy injection: $1,081 per percentage point
- Zepbound: $564 per percentage point
Value-Based Metrics
Cost per Quality-Adjusted Life Year:
- Zepbound: Most favorable due to high efficacy
- Wegovy: Moderate value proposition
- Foundayo: Higher cost per outcome but oral convenience
Selection Criteria Based on Data
For Maximum Weight Loss (>20%)
Recommended Options:
- Zepbound 15mg (22.5% average)
- Wegovy 7.2mg (20.7% average)
- Zepbound 10mg (21.4% average)
For Moderate Weight Loss (10-15%)
Recommended Options:
- Wegovy 2.4mg (14.9% average)
- Oral Wegovy (13.9% average)
- Foundayo (12.4% average)
For Cost-Sensitive Patients
Best Value Options:
- Oral Wegovy with intro pricing
- Foundayo with Lilly Direct
- Generic/compounded options (off-label)
The data clearly shows tirzepatide-based medications leading efficacy rankings, while oral options provide more accessible entry points with meaningful but moderate weight loss results.
Medical disclaimer: This content is for informational purposes only and is not medical advice. Consult a licensed healthcare provider before starting any treatment.
Health Disclaimer: BestMedsHub is not a healthcare provider, telehealth service, pharmacy, or medical organization. We do not prescribe medication, diagnose conditions, render medical opinions, or facilitate clinical consultations. All content is for general informational and comparison purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified physician, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any treatment, medication, supplement, or health program. Never disregard professional medical advice or delay seeking it because of anything you have read on this site. If you think you may have a medical emergency, call your local emergency number immediately.
FDA & Prescription Medication Disclaimer: Prescription medications referenced on this page are available only through a licensed healthcare provider after a clinical evaluation, and may not be appropriate or safe for everyone. Any statements regarding dietary supplements, wellness products, or off-label uses have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary and are not guaranteed. Always read the medication guide and consult your prescriber and pharmacist about side effects, contraindications, and drug interactions.
